Researchers at Brigham and Women's Hospital have found that the arthritis medication upadacitinib may significantly reverse severe hair loss. The study, which involved nearly 1,400 participants, suggests that the drug can help patients regrow substantial scalp coverage in as little as six months.
The 55 percent success rate for high-dose upadacitinib
In two international trials led by dermatologists, the efficacy of upadacitinib varied based on the dosage administered to patients aged 12 to 64. As reported by the research team at Brigham and Women's Hospital, approximately 45 percent of those taking a 15mg daily dose achieved at least 80 percent hair coverage on their scalp after 24 weeks. For those on the higher 30mg dose, the success rate rose to 55 percent, compared to a mere 3.4 percent for the placebo group.
The results were particularly striking for long-term sufferers. According to the findings published in JAMA Dermatology, roughly one in five patients receiving the higher dose achieved complete hair regrowth after six months of treatment. Beyond scalp coverage, many participants also reported improvements in the growth of their eyelashes and eyebrows.
Stopping the immune system's assault via JAK inhibitors
Upadacitinib belongs to a class of medicines known as JAK inhibitors, which function by preventing the immune system from attacking specific tissues. While these drugs are traditionally used to stop the immune system from attacking joints in arthritis patients, they appear to work similarly for alopecia areata by protecting hair follicles from autoimmune destruction.
The transition of this drug from arthritis management to dermatological treatment carries economic implications. For instance, the report notes that the medication costs the NHS roughly £28 per pill. While the study identified common side effects such as acne and upper respiratory infections, researchers stated that no new safety concerns were identified during the clinical trials.
A lifeline for the 400,000 Britons with alopecia areata
This condition is distinct from the common pattern baldness that affects a vast majority of men and women as they age. For the approximately 400,000 people in Britain living with alopecia areata, the psychosocial burden can be profound,as the disease can cause total body hair loss within weeks. High-profile figures, such as TV presenter Gail Porter, have highlighted the visibility of the condition after losing all her hair in 2005.
Current medical options for the disorder remain limited. While some patients experience spontaneous regrowth, those who have lost more than half of their hair or have experienced complete hair loss at any stage face only a 10 percent chance of a full recovery without intervention.. This creates a significant unmet need for the more effective therapies suggested by the upadacitinib trials.
The mystery of whether stress and infection trigger the condition
Despite the clinical progress, the exact biological triggers for alopecia areata remain unverified. While the British Association of Dermatologists has listed previous infections and high stress levels as potential triggers, experts note that these links may be purely coincidental rather than causal. Additionally, while the condition has been linked to thyroid disease, vitiligo, and type 1 diabetes,the precise mechanism that initiates this specific autoimmune response is still not fully understood.
Comments 0